Ehring B, Biber K, Upton T M, Plosky D, Pykett M, Rosenzweig M
Cytomatrix, Woburn, MA 01801, USA.
Cytotherapy. 2003;5(6):490-9. doi: 10.1080/14653240310003585.
An optimal system for the expansion of pluripotent HPCs would ideally eliminate the use of cytokines and animal-derived serum. We have shown previously that a 3D, tantalum-coated porous biomaterial (Cytomatrix) supports the maintenance and expansion of human BM HPCs in the absence of cytokines.
Umbilical cord blood (UCB) derived HPC were cultured in the Cytomatrix in the absence of exogenous cytokines. Phenotype was determined using FACS. Colony-forming units (CFU) activity was evaluated. Engraftment capacity was evaluated by transplanting the expanded cells into non-obese diabetic (NOD)/SCID mice.
We describe the expansion of HPCs from UCB using the Cytomatrix system. When UCB-derived CD34(+) cells were cultured in the Cytomatrix system for 2 weeks we observed an increase in the number of nucleated cells (3-fold) and CFU (2.6-fold). The number of CD45(+) and CD34(+) cells both increased three-fold. Trends demonstrated an increase in the frequency of CD34(+)C38(-) cells, and an increase in both CD34(+)C33(+) cells and CD34(+)C61(+) cells. No expansion of T or B lymphocytes was observed. When expanded UCB cells from the Cytomatrix were injected into sub-lethally irradiated NOD/SCID mice, human cells were detected in the murine peripheral blood and BM 6 weeks post-transplantation.
This unique approach to the expansion of UCB cells in a serum-free, cytokine-free environment may provide expansion of HPCs with multi-lineage engraftment capability that could be used clinically.
用于多能造血祖细胞(HPCs)扩增的理想系统应能避免使用细胞因子和动物源血清。我们之前已经表明,一种三维的、钽涂层多孔生物材料(细胞基质)在无细胞因子的情况下能支持人骨髓HPCs的维持和扩增。
将脐血(UCB)来源的HPCs在无外源性细胞因子的细胞基质中培养。使用流式细胞术(FACS)确定表型。评估集落形成单位(CFU)活性。通过将扩增后的细胞移植到非肥胖糖尿病(NOD)/重症联合免疫缺陷(SCID)小鼠中来评估植入能力。
我们描述了使用细胞基质系统对UCB来源的HPCs进行扩增的情况。当将UCB来源的CD34(+)细胞在细胞基质系统中培养2周时,我们观察到有核细胞数量增加了3倍,CFU增加了2.6倍。CD45(+)和CD34(+)细胞数量均增加了3倍。趋势显示CD34(+)C38(-)细胞频率增加,CD34(+)C33(+)细胞和CD34(+)C61(+)细胞均增加。未观察到T或B淋巴细胞的扩增。当将来自细胞基质的扩增UCB细胞注射到经亚致死剂量照射的NOD/SCID小鼠中时,在移植后6周在小鼠外周血和骨髓中检测到人类细胞。
这种在无血清、无细胞因子环境中扩增UCB细胞的独特方法可能会提供具有多谱系植入能力的HPCs扩增,可用于临床。